195 related articles for article (PubMed ID: 24496072)
1. Effects of centrally acting angiotensin converting enzyme inhibitors on functional decline in patients with Alzheimer's disease.
O'Caoimh R; Healy L; Gao Y; Svendrovski A; Kerins DM; Eustace J; Kehoe PG; Guyatt G; Molloy DW
J Alzheimers Dis; 2014; 40(3):595-603. PubMed ID: 24496072
[TBL] [Abstract][Full Text] [Related]
2. Effects of centrally acting ACE inhibitors on the rate of cognitive decline in dementia.
Gao Y; O'Caoimh R; Healy L; Kerins DM; Eustace J; Guyatt G; Sammon D; Molloy DW
BMJ Open; 2013; 3(7):. PubMed ID: 23887090
[TBL] [Abstract][Full Text] [Related]
3. A multicenter, blinded, randomized, factorial controlled trial of doxycycline and rifampin for treatment of Alzheimer's disease: the DARAD trial.
Molloy DW; Standish TI; Zhou Q; Guyatt G;
Int J Geriatr Psychiatry; 2013 May; 28(5):463-70. PubMed ID: 22718435
[TBL] [Abstract][Full Text] [Related]
4. Effect of Visit-to-Visit Blood Pressure Variability on Cognitive and Functional Decline in Mild to Moderate Alzheimer's Disease.
O'Caoimh R; Gao Y; Svendrovski A; Illario M; Iaccarino G; Yavuz BB; Kehoe PG; Molloy DW
J Alzheimers Dis; 2019; 68(4):1499-1510. PubMed ID: 30909214
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial.
Wilcock GK; Black SE; Hendrix SB; Zavitz KH; Swabb EA; Laughlin MA;
Lancet Neurol; 2008 Jun; 7(6):483-93. PubMed ID: 18450517
[TBL] [Abstract][Full Text] [Related]
6. Brain-penetrating angiotensin-converting enzyme inhibitors and cognitive change in patients with dementia due to Alzheimer's disease.
de Oliveira FF; Bertolucci PH; Chen ES; Smith MC
J Alzheimers Dis; 2014; 42 Suppl 3():S321-4. PubMed ID: 24577465
[TBL] [Abstract][Full Text] [Related]
7. Cognitive Impairment Precedes and Predicts Functional Impairment in Mild Alzheimer's Disease.
Liu-Seifert H; Siemers E; Price K; Han B; Selzler KJ; Henley D; Sundell K; Aisen P; Cummings J; Raskin J; Mohs R;
J Alzheimers Dis; 2015; 47(1):205-14. PubMed ID: 26402769
[TBL] [Abstract][Full Text] [Related]
8. Angiotensin-converting enzyme inhibitors and Alzheimer's disease progression in older adults: results from the Réseau sur la Maladie d'Alzheimer Français cohort.
Soto ME; van Kan GA; Nourhashemi F; Gillette-Guyonnet S; Cesari M; Cantet C; Rolland Y; Vellas B
J Am Geriatr Soc; 2013 Sep; 61(9):1482-8. PubMed ID: 24000874
[TBL] [Abstract][Full Text] [Related]
9. Can angiotensin-converting enzyme inhibitors impact cognitive decline in early stages of Alzheimer's disease? An overview of research evidence in the elderly patient population.
Rygiel K
J Postgrad Med; 2016; 62(4):242-248. PubMed ID: 27763482
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the efficacy, safety and tolerability of orally administered BI 409306, a novel phosphodiesterase type 9 inhibitor, in two randomised controlled phase II studies in patients with prodromal and mild Alzheimer's disease.
Frölich L; Wunderlich G; Thamer C; Roehrle M; Garcia M; Dubois B
Alzheimers Res Ther; 2019 Feb; 11(1):18. PubMed ID: 30755255
[TBL] [Abstract][Full Text] [Related]
11. Cohort Effects in Progression Rate on Cognitive and Functional Measures in an Alzheimer's Disease Clinical Cohort.
Pavlik VN; Chan W; Darby E
J Alzheimers Dis; 2019; 71(2):659-669. PubMed ID: 31424408
[TBL] [Abstract][Full Text] [Related]
12. Early- versus late-onset Alzheimer's disease in clinical practice: cognitive and global outcomes over 3 years.
Wattmo C; Wallin ÅK
Alzheimers Res Ther; 2017 Aug; 9(1):70. PubMed ID: 28859660
[TBL] [Abstract][Full Text] [Related]
13. Cognitive and functional decline and their relationship in patients with mild Alzheimer's dementia.
Liu-Seifert H; Siemers E; Sundell K; Price K; Han B; Selzler K; Aisen P; Cummings J; Raskin J; Mohs R
J Alzheimers Dis; 2015; 43(3):949-55. PubMed ID: 25125457
[TBL] [Abstract][Full Text] [Related]
14. The effects of metrifonate on the cognitive, behavioral, and functional performance of Alzheimer's disease patients. Metrifonate Study Group.
Raskind MA; Cyrus PA; Ruzicka BB; Gulanski BI
J Clin Psychiatry; 1999 May; 60(5):318-25. PubMed ID: 10362441
[TBL] [Abstract][Full Text] [Related]
15. Longitudinal Neuropsychological Outcome in Taiwanese Alzheimer's Disease Patients Treated with Medication.
Yang YH; Wu MN; Chou PS; Su HC; Lin SH; Sung PS
Curr Alzheimer Res; 2018 Mar; 15(5):474-481. PubMed ID: 29032750
[TBL] [Abstract][Full Text] [Related]
16. A randomized, controlled trial of doxycycline and rifampin for patients with Alzheimer's disease.
Loeb MB; Molloy DW; Smieja M; Standish T; Goldsmith CH; Mahony J; Smith S; Borrie M; Decoteau E; Davidson W; McDougall A; Gnarpe J; O'DONNell M; Chernesky M
J Am Geriatr Soc; 2004 Mar; 52(3):381-7. PubMed ID: 14962152
[TBL] [Abstract][Full Text] [Related]
17. Is functional decline necessary for a diagnosis of Alzheimer's disease?
Park KW; Pavlik VN; Rountree SD; Darby EJ; Doody RS
Dement Geriatr Cogn Disord; 2007; 24(5):375-9. PubMed ID: 17914262
[TBL] [Abstract][Full Text] [Related]
18. Neuropsychiatric Symptoms in Alzheimer's Disease Are the Main Determinants of Functional Impairment in Advanced Everyday Activities.
Delgado C; Vergara RC; Martínez M; Musa G; Henríquez F; Slachevsky A
J Alzheimers Dis; 2019; 67(1):381-392. PubMed ID: 30584142
[TBL] [Abstract][Full Text] [Related]
19. ABT-126 monotherapy in mild-to-moderate Alzheimer's dementia: randomized double-blind, placebo and active controlled adaptive trial and open-label extension.
Gault LM; Lenz RA; Ritchie CW; Meier A; Othman AA; Tang Q; Berry S; Pritchett Y; Robieson WZ
Alzheimers Res Ther; 2016 Oct; 8(1):44. PubMed ID: 27756421
[TBL] [Abstract][Full Text] [Related]
20. A longitudinal study of Alzheimer's disease: rates of cognitive and functional decline.
Suh GH; Ju YS; Yeon BK; Shah A
Int J Geriatr Psychiatry; 2004 Sep; 19(9):817-24. PubMed ID: 15352138
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
